epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

Neurology

Traffic air pollution exposure linked to higher amounts of amyloid plaques in Alzheimer’s patients

March 4, 2024

card-image

This cross-sectional study investigates the association between traffic-related PM2.5 and Alzheimer’s disease (AD) hallmark pathology, including effect modification by APOE genotype, in an autopsy cohort. The study findings suggest that people with higher exposure to traffic-related air pollution were more likely to have high amounts of amyloid plaques in their brains associated with AD after death.

  • Brain tissue donors who died before 2020 were examined for AD pathology, including the Braak stage, Consortium to Establish a Registry for AD (CERAD) score, and combined AD neuropathologic change (ABC) score. Traffic-related PM2.5 concentrations were also modeled for the metro-Atlanta area during 2002-2019.
  • Among the 224 participants, the mean age of death was 76 years, and 57% had at least 1 APOE ε4 copy.
  • Traffic-related PM2.5 was significantly associated with the CERAD score for the 1-year exposure window (odds ratio [OR] 1.92; 95% confidence interval [CI] 1.12-3.30) and the 3-year exposure window (OR 1.87; 95% CI 1.01-3.17).
  • PM2.5 was also associated with higher Braak stage and ABC score, albeit nonsignificantly.
  • The strongest associations between PM2.5 and neuropathology markers were among those without APOE ε4 alleles (e.g., for the CERAD score and 1-year exposure window, OR 2.31; 95% CI 1.36-3.94), though interaction between PM2.5 and APOE genotype was not statistically significant.

Source:

Christensen GM, et al. (2024, March 12). Neurology. Association of PM2.5 Exposure and Alzheimer Disease Pathology in Brain Bank Donors-Effect Modification by APOE Genotype. https://pubmed.ncbi.nlm.nih.gov/38382009/

Trending icon

TRENDING THIS WEEK

EPOCRATES CME

View Catalog

view all CME activities
learn more about epocrates plus
Clinical FAQ icon

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information